November 22, 2021
San Antonio, TX – Methodist Hospital | Texsan was the first in South Texas to implant Abbott’s Amplatzer Amulet device after being approved by the FDA, which represents a long-standing commitment to excellence in cardiovascular medicine. This device is the first and only minimally invasive treatment option to offer immediate closure to the left atrial appendage. The Amplatzer Amulet device was created to treat people with atrial fibrillation (A-fib), the most common sustained cardiac arrhythmia. A-fib is an irregular and often very rapid heart rhythm that can lead to blood clots in the heart and increase the risk of stroke, heart failure and other heart-related complications.
“The Amulet device opens the door for different anatomical variation which otherwise would be difficult to perform with the other devices,” said Javier Roman-Gonzalez, M.D., who served as lead surgeon of this procedure. The alternative option for A-fib, however, takes about 45 days for the left atrial appendage to seal properly, thus delaying functionality.
Dr. Roman-Gonzalez highlights a number of advantages regarding the Amplatzer Amulet device implant. The amulet’s dual-seal approach better prevents blood clots from migrating to the brain. Recovery is much quicker and does not require systemic anticoagulation regimens such as blood thinners. After thorough research and clinical trials, final results are shown to be far more effective and safe. For more information about this service at Methodist Hospital | Texsan, please visit https://sahealth.com/specialties/cardiology?location=methodist-hospital-texsan.